Indivior PLC (LON:INDV – Get Free Report)’s stock price traded down 15.7% on Thursday . The company traded as low as GBX 548.71 ($6.90) and last traded at GBX 732 ($9.21). 1,888,371 shares traded hands during mid-day trading, an increase of 166% from the average session volume of 709,477 shares. The stock had previously closed at GBX 868 ($10.92).
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group restated a “buy” rating and set a GBX 1,800 ($22.65) price objective on shares of Indivior in a report on Tuesday, December 17th.
Read Our Latest Analysis on Indivior
Indivior Stock Performance
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Read More
- Five stocks we like better than Indivior
- Earnings Per Share Calculator: How to Calculate EPS
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- What Are Some of the Best Large-Cap Stocks to Buy?
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Trading Halts Explained
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.